PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/718,082		
Filing Date	November 20, 2003		
First Named Inventor	Linda S. HIGGINS		
Art Unit	Not Yet Assigned		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	SCI5221USNP		

			NON PATENT LITERATURE DOCUMENTS		
Examiner Initials* Cite No.1		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		ı	Attisano, et al., Science, May 31, 2002, pgs 1646-1647, Volume 296		
	-	2	Bottinger, et al., Journal of the American Society of Nephrology, 2002, pgs 2600-2610, volume 13		
		3	Eberwine, et al., Proc Natl Acad Sci USA, April 1992, pgs 3010-3014, Volume 89		
		4	Itoh, et al., Eur J. biochem, 2000, pgs 6954-6967, Volume 267		
		5	Kerr, et al., Genet Res. Camb., 2001, pgs 123-128, Volume 77		
		6	Massague, Joan, Ann. Rev. Cell. Biol., 1990, pgs 597-641, Volume 6		
		7	Miyazono, et al., Advances in Immunology, 2000, pgs 115-157, Volume 75		
Î		8	Sporn, et al., Handbook of Experimental Pharmacology, 1990, pgs 419-458, Volume 95		
$\overline{\Psi}$,	9	Topper, James N., Trends in Cardiovasc Med, 2000, pgs 132-137, Volume 10		
/A.H./ ₁₀ Whitman, Malcom, Genes Development, 1998, pgs 2445-2462,		Whitman, Malcom, Genes Development, 1998, pgs 2445-2462, Volume 12			

Examiner	l Date	11/28/2007
I I/Angriao Hoiti		11/20/2007
Signature /Allulide Floto	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.